---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071566"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:35:12.914187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B

## Summary
- Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.
- GAAP net loss Q4 $412.2M ($3.93/share) vs Q4 2024 net income $159.0M; full-year GAAP net loss $713.4M.
- Ended 2025 with ~$1.0B cash; refinanced $291.4M of 2027 notes to 2030 notes, removing near-term debt.
- Japan launch of ELEVIDYS by Chugai in Feb 2026; eligible for $40M milestone. Positive 3-year EMBARK results.
- Approval to begin Phase 1 trial of SRP-1005 (siRNA) for Huntington’s disease; Phase 1/2 SRP-1003 for DM1 advancing.

## SEC filing metadata
- accession: 0001193125-26-071566
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/0001193125-26-071566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071566
- JSON: https://secwatch.observer/filing/0001193125-26-071566.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.